Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer

Recruiting · NCT06772935 · Interventional (participants receive a specific treatment) · Lead sponsor: Affiliated Hospital of Qinghai University

Interventions studied

Electro-acupuncture

Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer

Age range

18 Years to 75 Years

Sex

Female

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Breast cancer patients diagnosed by pathology;
EOOG score is 0 or 1;
The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);
⑤ Previously received taxane chemotherapy for more than 6 months;
⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;
⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
Accept regular follow-up visits; ⑨ There is complete pathological data available.

Non breast cancer patients;
Received electroacupuncture treatment within 6 months prior to the start of the study;
Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;
Prior to enrollment, there was a history of peripheral neuropathy;
Unstable heart disease or myocardial infarction within the first 6 months of the study;
⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;
⑦ Uncontrolled epilepsy patients with uncontrolled seizures;
⑧ Merge with other malignant tumor patients;
⑨ Pregnancy and lactation period;
⑩ Refusal to join clinical trial patients

1 location listed.